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ALFONSO ET AL.: Conflict of Interest Policies and Disclosures Requirements Among European Society of
Cardiology National Cardiovascular Journals. Disclosure of potential conflicts of interest (COI) is used by biomedical
journals to guarantee credibility and transparency of the scientific process. COI disclosure, however, is not
systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the
implementation of uniform vehicles for COI disclosure. This paper provides a comprehensive editorial perspective
on classical COI-related issues. New insights into current COI policies and practices among European Society of
Cardiology national cardiovascular journals, as derived from a cross-sectional survey using a standardised
questionnaire, are discussed. (J HK Coll Cardiol 2012;20:3-14)
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Introduction
The scientific process relies on trust and
credibility.1-5 The scientific community demands high
ethical standards in biomedical research and the
publication of scientific content.1-5 During the past
decade, disclosure of conflicts of interest (COI) (also
called competing loyalties, competing interests, or dual
commitments) has been considered as key to
guaranteeing the credibility of the scientific process.6-10
Biases in design, analysis, and interpretation of studies
may arise when authors or sponsors have vested
interests.6-10 Therefore, COI should be made clear to the
readers to facilitate their own judgement and
interpretation of their relevance and potential
implications. Authors are responsible for fully
disclosing potential COI.6-10 Failure to do so has shaken
the confidence of the public, health professionals and
scientists in the peer-reviewed medical literature.6-10
According to the International Committee of
Medical Journal Editors (ICMJE), COI exist when an
author (or the author's institution), reviewer, or editor
has financial or personal relationships that
inappropriately influence (bias) his or her actions.1,11,12
The potential for COI exists regardless of whether the
individual believes that the relationships affect his or
her scientific judgement. Aside from financial
4

relationships, COI may emerge from personal
relationships, academic competition, and intellectual
passion. To prevent ambiguity, authors should be
explicitly asked to state whether COI exist or do not
exist. Editors should publish this information if they
believe that it is important in judging the manuscript.1,11,12
Traditionally, biomedical journals have followed
standard practices to ensure COI disclosure. Further
efforts to improve transparency and protect the integrity
of research, including specific recommendations and
guidelines to disclose COI, have been recently proposed
by many organisations.1-10 However, ensuring adequate
reporting of all sources of financial support is becoming
increasingly challenging for editors as a result of the
growing complexity of funding mechanisms.
Furthermore, journals have different policies about COI
disclosure which can cause confusion as the same author
may report different information in different journals
which, in turn, might jeopardize the confidence of the
readers.11,12 To overcome these problems, the ICMJE
proposed the use of a common vehicle to report COI
and, in October 2009, launched an electronic 'uniform'
format for COI disclosure.11,12
The Editors' Network of the European Society of
Cardiology (ESC) is committed to promoting the
dissemination and implementation of high quality
editorial standards among ESC National Societies
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Cardiovascular Journals (NSCJ). 13-16 This report
examines the issue of COI from a global and didactic
perspective and provides new insights into current
policies and practices among ESC NSCJ.

Conflicts of Interest Questionnaire
and Survey
To determine the status of COI and disclosure
requirements among ESC NSCJ a web-based,
comprehensive, structured, and standardised
questionnaire was specifically devised. The
questionnaire was exhaustive and dealt with all relevant
editorial topics related to COI. Previous publications
on COI (from Year 2005 to 2010) were retrieved from
PubMed (Medline search term 'conflict of interest',
'competing interest', and 'disclosure') and carefully
reviewed to identify issues relevant to COI. Items
included in the questionnaire were eventually
determined after an internal discussion among the
nucleus members of the Editors' Network. For the sake
of simplicity, some related items and confusing or
redundant topics were subsequently removed from the
final questionnaire. Eventually, a total of 48 different
items were included in the survey. Questions were
grouped into three main areas of interest: (1) authors;
(2) reviewers; (3) editors. Furthermore, additional
feedback about the interest generated by the ICMJE
'uniform' COI disclosure initiative was also explicitly
requested. Spaces for free text comments were made
available for each main area of interest.
In June 2010 the web-based survey was sent from
the ESC European Heart House to all editors-in-chief
of the ESC NSCJ and, in a second wave (July 2010), to
the ESC Affiliated Cardiac Societies. A specific claim
was made for the editor-in-chief in person to complete
the survey. The invitation suggested that a meeting
between the editor-in-chief, associated editors, and
corresponding journal staff should be organised, to
discuss the results of the requested information, before
returning the questionnaire. A URL link to the webbased survey was provided in the invitation letter to
allow editors to enter the survey. When no answer was
obtained the corresponding National Cardiac Society
was contacted directly. Conventional mailing was also
J HK Coll Cardiol, Vol 20

used as required. Up to five separate requests were sent
over the year and thereafter missing journals were
classified as non-responders.
The final electronic records were carefully
analysed by ESC personnel at the European Heart House
and by the nucleus members of the ESC Editors'
Network. Attention was paid to detecting missing
data, major inconsistencies, or errors. Additional
clarifications were requested from the corresponding
editors as needed. Data are presented as global results
and anonymised for individual journals.

Conflicts of Interest Survey Results
A total of 46 journals answered the survey. Of
these, 35 belong to the ESC NSCJ and 11 to journals of
Affiliated Cardiac Societies. This represents a response
of 83% (35/42) of known NSCJ and 58% (11/19) for
Affiliated Cardiac Societies. ESC NSCJ are highly
heterogeneous in objectives, format, and in scientific
content.13 Accordingly, some editors declined to answer
the survey because they felt that COI policies did not
apply to their journals (lack of original articles, small
bulletins, contents with just social news, etc.) (data not
shown).
Table 1 summarises the main data regarding
authors' COI. Nearly, half of the journals had a specific
policy on author COI. In most cases, emphasis was only
on financial COI and on COI directly related to the
submitted work. Few journals provided definitions or
examples of COI. In nearly all cases where COI were
requested, this policy affected all kinds of submitted
articles. Written attestation by the authors was widely
requested. However, procedures to verify the accuracy
of authors' COI disclosure were rarely implemented,
although, under special circumstances, most editors
eventually contact authors to clarify COI-related issues.
Policies to deal with authors who fail to disclose COI
were seldom in place. In most journals, the editors
decided when authors' COI should be published, but, in
some journals, this information was systematically
published (Table 1).
Table 2 discloses data related to reviewers' COI.
Only one-quarter of the journals had policies for
reviewers' COI. In more than half of the journals,
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Table 1. Journals policies on authors' conflicts of interest
1. The journal has a specific policy on authors' COI: 20/45 (44%)
If Yes:
a. Described in the instruction for authors: 19/20 (95%)
b. Described in dedicated forms required for manuscript submission: 12/19 (63%)
2. The journal provides definition of different types of COI: 6/45 (13%)
3. The journal provides examples of different COI: 5/45 (11%)
4. COI are detailed by items and specified according to journal's definition: 9/45 (20%)
If Yes:
a. Financial COI are specifically considered: 8/9 (89%)
b. Non-financial COI are specifically considered: 2/9 (22%)
5. Editors recommend an "inclusive" policy where all potential COI (even those minor and vaguely related)
should be disclosed: 13 /44 (30%)
6. Editors favour a "restrictive" policy where only potential COI that are relevant and directly related to the
submitted work, should be disclosed: 19/42 (45%)
7. Resources from third parties received via the authors' institution are considered: 8/42 (19%)
8. Financial relationships involving family members are specified: 4/44 (9%)
9. COI are just disclosed as free text directly by the authors: 29/40 (73%)
10. Authors must submit a written attestation of potential COI: 18/44 (41%)
If Yes:
a. Signature is required only from the corresponding/responsible author: 10/18 (55%)
b. Every single author should sign the form: 6/18 (33%)
11. Authors' COI disclosures apply to "all" submitted articles: 23/44 (52%)
12. Specific procedures are followed to verify that authors' COI disclosures are accurate: 6/44 (14%)
13. Under specific circumstance, efforts are made to contact authors owing to concerns about disclosed or
undisclosed COI (e.g., complain by reviewers/readers): 27/41 (66%)
14. Specific policies to deal with authors who fail to disclose COI of published papers: 11/45 (24%)
15. Specific policies to "restrict" author publication of articles with a stated COI: 10/44 (23%)
16. The journal "publishes" all the authors' COI disclosures in all submissions: 13/40 (33%)
17. The editors decide, on an individual basis, when authors' COI should be "published": 23/43 (53%)
18. If authors' COI are not published, the information is made available upon request: 21/46 (46%)
Data from the 46 journals answering the questionnaire (number of journals answering each question is presented). Not all
journals responded to all questions. COI, conflicts of interest
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Table 2. Journals' policies on peer-reviewers' conflicts of interest
1. The journal has a specific policy on reviewers' COI: 11/43 (25%)
2. Reviewers are required to explicitly state whether they have potential COI: 10/43 (23%)
3. Reviewers must submit a written attestation of potential COI: 7/43 (16%)
4. Frequency of request to disclose potential COI: only first invitation:7/46 (15%); always 10/46 (22%);
yearly 5/46 (11%)
5. Specific procedures are followed to verify that peer-reviewers' COI disclosures are accurate: 5/44 (11%)
6. It is suggested to reviewers that they "decline" the invitation if potential COI exists: 21/39 (54%)
7. There is a policy for "recusal" of reviewers with a declared COI: 6/42 (14%)
8. Peer-reviewers' COI are always published: 1/44 (2%)
9. Editors decide, on an individual basis, when reviewers' COI should be published: 20/44 (45%)
10. If reviewers' COI are not published, the information is made available upon request: 15/46 (33%)
COI, conflicts of interest

reviewers were asked to decline the invitation to review
if potential COI existed. However, recusal of reviewers
due to potential COI was rare.
Table 3 displays the status of editors' COI among
the corresponding journals. In most cases, policies in
this regard were not implemented. Furthermore, very
few journals had policies for delegating decisions to
other editors or to invited guest editors. Only one-third
of the editors were familiar with the new 'Uniform
Disclosure Form' ICMJE initiative when they received
the survey invitation. However, 90% of the editors
considered the ICMJE COI proposal of potential value
to their particular journals and most of them declared
that they were willing to implement it within a relatively
short period of time (Table 4).

Discussion
Industry-sponsored studies: friend or foe?
Research is becoming progressively complex and
quality standards increasingly demanding.17-24 As a
result, conducting clinical studies is becoming more
expensive and the role of sponsors to ensure the viability
of research projects is becoming critical. However,
funding from different sources may directly affect
investigators and COI may inappropriately influence
their actions or judgement.17-24 Subtle biases in design
and interpretation may arise when a sponsor stands to
gain from the report.17
J HK Coll Cardiol, Vol 20

Pharmaceutical and technological companies are
responsible for most important advancements in medical
knowledge.17-24 Patients, doctors, and society as a whole
benefit from this unique effort and should be grateful
for the research commitment by the industry. More
than 75% of all clinical trials are funded by drug
companies.25,26 Likewise, the bulk of research has moved
from academic centres to direct contracts between
sponsors and private organisations. 27,28 For profit,
contract research organisations currently consume more
than 60% of research funding from industry.25-28 This
could be a result of their ability to complete trials more
rapidly than academic institutions.8,25 This phenomenon
explains the gradual loss of the academic establishment's
influence on the 'research agenda'.25-29 Although the
most cited articles continue to be generated by authors
with academic affiliations, the number of trials
financed exclusively by industry has increased
exponentially.30
This paradigm shift has major consequences.25-29
First, many scientifically relevant issues are
decreasingly likely to be investigated (orphan studies).
Second, many studies8,31,32 suggest that in comparison
with non-sponsored research, sponsored trials are
published less frequently, raising the concern of
publication bias. 29 Although the industry has been
blamed for preferential publication of studies with
positive outcomes, this problem also affects
government-funded research.8,31-35 To reduce the effect
of publication bias, trials must be registered in publicly
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Table 3. Journals' policies on editors' conflicts of interest
1. The journal has a specific policy on editors' COI: 8/45 (18%)
2. Editors must submit a written attestation on potential COI: 6/8
3. Frequency to disclose potential COI: only when appointed 5/6; yearly 1/6
4. Specific procedures are followed to verify that editors' COI disclosures are accurate: 3/8
5. There is a policy for "recusal" of editors with a declared COI: 3/8
6. There is a policy for "delegating" handling decision to other (invited) editors: 4/7
7. Editors' COI are always published: 2/7
8. If Editors' COI are not published, the information is made available upon request: 5/6
COI, conflicts of interest

Table 4. Feed-back on the ICJME "uniform disclosure form" initiative
1. Editor was familiar with the ICMJE initiative "before" receiving the survey: 15/42 (36%)
2. The initiative was considered of value the "particular" journal: 38/42 (90%)
3. Editors willing to implement the initiative within 3 years: 31/46 (67%)
4. Main perceived advantages of the initiative (top 5):
a. Provides a common "uniform" platform for all journals: 42
b. All relevant information regarding COI is nicely presented and explained: 18
c. Allows easy update of the requested information: 12
d. Facilitates sequential submissions (if the paper is rejected by a journal): 11
e. Allows archiving of the requested information: 10
5. Main perceived disadvantages of the initiative (top 5):
a. Increases the complexity of the submission process: 29
b. Publishing in the journal all potential COI of every author is not feasible: 17
c. Verification of the disclosed/undisclosed COI remains impossible: 17
d. Increases editorial bureaucracy: 15
e. Too detailed and exhaustive: 14
f. The meaning of some potential COI (travel grants to meetings, etc.) might be perceived differently by
American and European authors/journals/readers: 14
COI, conflicts of interest; ICMJE, International Committee Medical Journals Editors

accessible repositories.29 Industry-supported research
has also been associated with multiple reporting of
studies with positive outcomes.8,36 This practice might
affect results of subsequent reviews, meta-analyses, and
even clinical practice guidelines. Alternatively, industry
sponsorship has been associated with publication delays
or restrictions.8
Finally, industry-sponsored trials have a threeto four-fold greater probability of obtaining favourable
results than their non-sponsored counterparts.8,31-33,37,38
Interestingly, all these differences do not appear to be
related to inferior methodology in industry-financed
trials. Bekelman et al8 performed a systematic review

8

of 1140 original studies demonstrating a statistically
significant association between industry sponsorship
and pro-industry conclusions. The study showed that
financial relationships between industry, scientific
investigators, and academic institutions were
widespread and that COI arising from these ties might
significantly influence biomedical research. It was
considered possible, however, that given limited
resources, industry became selective enough to fund
only potentially 'wining treatments'.8 More recently, in
a provocative study that included 324 cardiovascular
trials published in the three medical journals with the
highest impact factors, Ridker and Torres39 analysed the
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probability of positive results according to the source
of finance. Industry-financed trials more frequently
obtained results favourable to drug or device than those
financed by not-for profit organisations. This was
particularly evident in trials using surrogate endpoints.39

Previous Editorial Surveys on
Conflicts of Interest
In 1997, Krimsky and Rothenberg found that only
16% of journals across all scientific disciplines had COI
policies.40 In addition, existing editorial policies were
often not readily available to submitting authors.41
However, a substantial increase in the prevalence of COI
disclosure occurred over time. Initially, most journals
only required authors to disclose potential COI.
Subsequently, journals encouraged authors to sign COI
disclosure statements. If signed statements are not
obtained from all authors, it remains possible that only
the first author has reviewed the COI policy of the
journal, leading to systematic under-reporting. 6
Interestingly, some journals that theoretically adhere
to ICMJE recommendations do not have clear COI
policies when critically analysed.6 However, the journals
with highest impact factors are more likely to have
published COI policies.6,41
To better characterise COI policies, in 2006,
Cooper et al7 performed a cross-sectional web-based
survey of a convenience sample of 135 editors of peerreviewed biomedical journals. The survey included
questions about the existence of specific policies for
authors, peer reviewers, and editors, specific restrictions
based on COI and the public availability of these
disclosures. Ninety-three per cent of journals reported
having an author COI policy but only 82% of these
required a written attestation. While 77% reported
collecting COI information on all author submissions,
only 57% published all author disclosures. Eleven per
cent of journals reported restricting author submissions
based on COI. A minority of journals reported having a
policy on reviewers' COI (46%) or editors' COI (40%);
among these, 25 and 31% of journals stated that they
require recusal of peer-reviewers and editors if they
report a COI. Only 3% of respondents published COI

J HK Coll Cardiol, Vol 20

disclosures of peer reviewers and 12% published editors'
COI disclosures, while 11 and 24%, respectively,
reported that this information was available upon
request. In this survey, estimates were directly provided
by the corresponding editors, but no information was
taken directly from the actual publications.7
Other studies were more critical and analysed the
information available directly from the journals yielding
a different perspective. Interestingly, some of these
studies focused on COI disclosures in cardiology.
Weinfurt et al 42 searched in PubMed for Englishlanguage articles published in 2006 that provided
evidence or guidance about the use of coronary artery
stents. As a premise, it was considered reasonable to
expect that authors' COI were disclosed in similar ways
in articles on the same topic published around the same
time. A total of 746 articles with 2985 authors published
in 135 journals were analysed. Articles were examined
to determine whether authors' financial interests were
consistently reported. Eighty-three per cent of the
articles did not contain disclosure statements for any
author, 72% did not identify any funding source and
only 6% of authors had an article with a disclosure
statement. Additionally, author disclosure statements
varied significantly from article to article. Notably,
articles published in journals that endorsed the ICMJE
guidelines were more likely to have disclosure
statements for all authors. Similarly, articles in which
all authors had disclosure statements were more likely
to appear in journals with higher impact factors (median
impact factor 11.6 vs. 3.1). These investigators
concluded that even rarely disclosed financial interests
were not disclosed consistently, suggesting that there
are problems with transparency in the cardiac literature
with potential implications for patient care. Data
suggested that the observed inconsistencies were a result
of both journals' policies and authors' behaviour.42 Many
would argue that an inconsistent system of disclosure
is more harmful than no disclosure at all.
More recently, Blum et al6 analysed COI policies
of the top 10% of medical journals according to their
impact factor. Instructions to authors and manuscript
submission documents were electronically searched for
phrases relating to COI using a standardised form. A
total of 262 journals were analysed. Of these, 85%
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requested COI disclosure in the instruction to authors
and an additional 4% in other submission documents.
Links to specific policies on COI were found within
the instruction for authors in only 25% of journals.
Although 77% of journals provided definitions on COI,
signed disclosure statements were required by only 54%
of journals. Travel grant disclosure was requested by
12% of journals. Interestingly, journal category
influenced COI disclosure requirements. This request
was higher for internal medicine journals than for
speciality journals, for journals in the top quartile
according to the impact factor, and for journals
endorsing the ICMJE guidelines.6
Our data on ESC NSCJ COI policies and
disclosure requirements suggest that this topic remains
controversial and is not uniformly addressed by journals.
We relied on self-reporting by journal editors. However,
given the anonymous nature of our survey, we do not
believe that there is any reason to question the accuracy
of their reports.

ICMJE Uniform Disclosure Initiative
In October 2009, the ICMJE proposed an
electronic 'uniform' format for COI disclosure.11 Four
main areas were addressed: authors' associations with
entities that supported the submitted manuscript
(indefinite time frame), associations with commercial
entities with potential interest in the general area of the
manuscript (time frame 36 months), financial
association of their spouse and children, and, finally,
non financial associations potentially relevant to the
submitted manuscript. Each author should disclose
resources received directly, or via the corresponding
institution, which were used to complete the
investigation. Additionally, all sources of revenues
relevant to the submitted work paid by any third party
before the submission and any relevant long-term
relationship, even if ended, should be disclosed.
Financial revenues should be disclosed regardless of
the amount. A guide for authors and a completed sample
was provided in a PDF format. The reporting form was
made available at www.icmje.org/coi_disclosure.pdf to
be downloaded, completed, and sent to the journal11 The

10

form can be saved and used again − adding updated
information − for a new manuscript. Each author should
submit a separate form and is responsible for the
accuracy and completeness of the submitted
information.11
The ICMJE allowed a period of beta-testing until
April 2010 when submission of suggestions was
encouraged.12 As a result of the feedback comments,
the form was modified. Concerns raised were mainly
technical and ethical regarding inquiries about nonfinancial associations. Accordingly, clarity was
enhanced for non-native English speakers (including a
glossary of terms). Additionally, owing to the difficulties
detected in defining non-financial COI, this section was
also modified to be less intrusive (currently presented
as an open query) while keeping its locus. Finally,
queries about COI in family members were removed
from the updated form.12
The idea behind this initiative was to facilitate
and standardise uniform disclosure of COI and to make
the process easier for authors and less confusing to
readers. This uniform 'universal' vehicle allows authors
to save the electronic forms that can be updated as
needed and eliminates the need for reformatting
disclosure information for each new submission.
Finally, this will eliminate apparent inconsistencies in
the report of COI as a result of different journal
policies.11,12

Additional Editorial Perspectives
Regarding Conflicts of Interest
Concerns about COI are not new. In his play
Le Malade Imaginaire Molière satirised the relationship
between the doctor and the druggist as they exploited
the hypochondriac Argan for their own economic
benefit. 21 Biomedical journals are particularly
vulnerable to COI-related problems. As Richard Smith,
the former editor-in-chief of the British Medical
Journal, stated that "the quality of the journal will bless
the quality of the drug". 43 Therefore, it is easy to
understand the extra scrutiny of industry-sponsored
research by reviewers and editors.33 Some editors require
that authors of industry-associated research have their
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data analysis confirmed by a different source and others
even ask for the raw data to be analysed by an
independent academic statistician.20,33 Some editors do
not commission editorial or review articles from authors
with potential COI as these may blur objectivity.19,44,45
These pieces rely especially on interpretation and
objectivity. However, assessing the importance of COI
in opinion articles may be challenging. The dilemma is
obvious: those authors with the greatest expertise are
usually those with clearer potential COI.44 Last, but not
least, editors should also avoid the existence of
marketing masquerading as education in their journals.
Of note, industry support accounts for most of the
funding of accredited continuing medical education
(CME) programmes.19 Some suggest that CME has
become an insidious vehicle for the aggressive
promotion of drugs and medical devices (even with offlabel indications). Others consider CME a marketing
machine and a lucrative process − with concealed
payments to doctors − that undermines the independence
of medical societies.19,46
Sometimes medical literature is produced in
obscure ways. Professional writers, hired by the
industry, may act as 'ghostwriters' to produce papers
for which credibility will be subsequently increased by
inviting academic physicians to act as a 'guest author'.33
Unfortunately, these guest authors rarely make
significant contributions to the design, analysis and data
interpretation.33 Conversely, many deserving industry
scientists may be removed from the byline directly by
the sponsors. Affiliation with a drug company should
not be viewed as evidence of wrongdoing because, as
previously emphasised, most important medical
discoveries are generated by the pharmaceutical
industry.
Journals typically use two main weapons to deal
with COI: disclosure and exclusion.44 However, as
discussed, policies for COI vary widely among editors.
Disclosure should not be considered as a panacea to
deal with COI but, from an editorial perspective, casting
daylight on the relationship between doctors and
pharmaceutical companies represents the best way to
untie this Gordian knot.44 Editors should decide whether
to publish the information disclosed by authors about
potential COI. Editors have the 'discretion' to decide
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whether the potential COI is important enough to be
revealed.6 However, it is unclear how editors decide
whether to publish disclosures. Moreover, the extent to
which such 'secret disclosure' may affect the integrity
of the journal or the published work remains unknown.7
Some journals systematically disclose all reported
potential COI.6 However, this strategy consumes major
editorial resources and has been blamed for introducing
prejudice in the judgement of manuscripts by readers
and for tainting the full content of the article. The value
of an exhaustive systematic disclosure of all potential
COI remains highly controversial. This practice does
not guarantee that the readers will be able to determine
whether COI are meaningful or not. Indeed, this practice
may be misleading because bias may be perceived when
not present and overlooked when relevant. Although
COI do not imply any improper behaviour, a
McCarthyesque reaction to the term would wrongly
support the presumption of guilty until proven
innocent. 23,33,47 The pendulum is swinging towards
increased oversight, but responsible editors should
ensure that their readers enjoy the sweet spot in the
middle, at least for the time being.
Editors are very busy and cannot conduct a
forensic check on every submitted trial. Our survey is
consistent with prior reports7 suggesting that almost no
journal has a formal policy of 'verification' of COI
disclosures.7 Editors are not policemen but, at the same
time, it becomes clear that some action is expected when
misconduct is detected. Many times editors behave as a
'toothless watchdog' regarding COI. Alternatively, other
editors suggest that allegation of under-reported COI
should be rigorously investigated.9 However, editors do
not have the resources required to conduct a full
investigation to clarify elusive and multifaceted COIrelated issues. In most cases, their final role is just to
raise the issue with the corresponding dean. Notably,
formal 'corrections' about COI are rarely published.
All authors of this review support the importance
of disclosing potential COI when a scientific paper is
submitted for consideration to any ESC NSCJ.
Moreover, when in doubt, it is better to err on the side
of over-disclosure and let the editors make the decision.
The ICMJE Uniform Disclosure Initiative represents a
milestone in this regard and paves the way for further
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transparency in biomedical publishing.11,12 Therefore,
we encourage ESC NSCJ to progressively adapt their
policies in order to be able to adhere to this editorial
proposal. However, in this journey, some potential
caveats should be carefully heeded. First, exhaustive
disclosure of multiple, minor and vaguely related
potential COI might 'dilute' the relevance of real major
COI that most readers would be interested to know.
Second, some relevant institutional COI are not openly
disclosed to all corresponding researchers and,
accordingly, these may be impossible to declare.
Third, many major journals frequently allow senior
international opinion leaders with clear (definitive and
well-known) COI to systematically declare the absence
of COI in their papers. Young scientists may perceive
this as confusing and disturbing while others will regard
this inconsistency as evidence that the whole process is
completely hypocritical. Finally, major sociocultural
differences among countries should also be taken into
account. Most European doctors (including most editors
in the byline of this article) frequently receive occasional
travel grants from diverse pharmaceutical companies
to attend medical society meetings and, up to now, these
have not been systematically disclosed as potential COI.
The situation, however, is quite different on the other
side of the Atlantic where such practices have been
considered inadequate or even misconduct for a number
of years. In North America, direct support (including
travel) of CME programmes by industry is prohibited
while this practice is considered acceptable in most
European countries.19 NSCJ editors should be alerted
to the need to deal with these vexing problems in their
respective journals in line with local policies and
practices.48 Progressive steps should be taken to ensure
a systematic approach to these COI-related editorial
issues. However, commonsense and reason should
prevail in order to achieve a balance between the
pragmatic and utopian.

Final Remarks
Consumers of medical scholarship expect a
reliable system of disclosure, in which journals and
authors make disclosures appropriately and consistently.
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There is a stigma surrounding the reporting of COI that
should be progressively overcome. The ESC has recently
defined a general policy for COI.49 This review provides
another framework to better understand COI from an
editorial perspective. This survey on ESC NSCJ COI
policies and disclosure requirements confirms that this
topic is poorly − and not uniformly − dealt with by
journals. Further actions are required to increase
awareness of the importance of COI disclosure and to
promote policies aimed at enhancing transparency in
biomedical research.
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